Keep pulling the thread on Vin Singh.
Large pharmaceutical companies experience a 50% failure rate in Phase 3 clinical trials.
Bullfrog AI believes it has discovered the genes that are the biological drivers for major depressive disorder, bipolar disorder, and schizophrenia using a unique dataset from the Lieber Institute for Brain Development.
Bullfrog AI has developed a proprietary causal AI capability that can generate 6 million models in 30 minutes.
In a pancreatic cancer study, Bullfrog AI's platform identified a patient subgroup and associated biomarkers that showed an increase in overall survival from approximately 2 months to 6 months.
Large pharmaceutical companies are beginning to acquire AI companies with the strategic goal of owning proprietary models rather than partnering for access.
Using its AI platform, Bullfrog AI discovered driver genes for neuropsychiatric diseases from the Lieber Institute's data in a matter of months, a task the institute had worked on for many years.
Vin Singh expects Bullfrog AI to close multiple deals with large pharmaceutical companies during 2026.
Vin Singh claims that over 90% of AI drug discovery partnership deals in the industry fail to meet their milestones.
The typical drug development process takes 10 to 15 years and costs between $1 billion and $2 billion.
Bullfrog AI secured a worldwide exclusive license from the Johns Hopkins University Applied Physics Lab (APL) for its AI platform for drug development applications.
Bullfrog AI's technology platform is agnostic to the stage of drug development and the specific disease area.
Bullfrog AI has launched a data preparation solution called BF Prep, designed to convert messy biomedical data into a clean, structured, AI-ready format.